Saiba Animal Health achieves collaboration milestone

The license execution triggered a significant upfront payment which Saiba Animal Health will use to further advance its technology and other pipeline candidates.

Dr. Gary T. Jennings, CEO of Saiba Animal Health AG commented: “This significant step in our collaboration was the result of a compelling preclinical data-set generated by the R&D teams of both parties over the course of the initial research agreement. We are very excited at the prospect of the formidable capabilities of our partner being used to advance the product candidate into development and hopefully to the market. Significantly, we consider our partner’s commitment due recognition of the potential of our platform technology to be translated into cost effective therapies for companion animals.”

Saiba Animal Health has developed a novel and innovative vaccine platform that is based on non-infectious virus-like particles in order to treat chronic inflammatory diseases, cancer and allergy in pets. Saiba Animal Health can easily adapt the innovative VLP vaccine platform to target any disease-associated molecule taking advantage of the latest and most effective innovations in human medicines, specifically monoclonal antibody therapy, and turn them into a new, efficacious and affordable class of veterinary vaccine-based medicine.

(Press release / SK)